Drug Trial Radar · NCT04934514
Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
97
Planned (sponsor's estimate)
Start
Jul 6, 2021
Primary completion
Dec 31, 2024
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- SUNHO(China)BioPharmaceutical CO., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of IAH0968 in patients with HER2-positive advanced solid tumors who have failed standard treatment.
Conditions
- Advanced Solid Tumor
Interventions
IAH0968Biological
IAH0968 is an investigational product.
GemcitabineDrug
Gemcitabine 1000 mg/m\^2 intravenous infusion
CisplatinDrug
Cisplatin 75 mg/m\^2 intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of adverse events (AEs) and SAEs (Phase Ⅰ)Time frame: 3 months after end event visit
- Dose limiting toxicities (DLTs) (Phase Ⅰ)Time frame: 21 days after first dose
- Objective response rate (ORR) in dose expansion (Phase Ⅱa)Time frame: Baseline through up to 2 years or until disease progression
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.